

Til alle brugere af AEM

To all users of EMED (English below)



VEDR. OBLIGATORISKE UDBEDRINGER EFTER AAALAC AKKREDITERINGSBESØG

24. MARTS 2023

(Please find the English version below)

BLEGDAMSVEJ 3B
KØBENHAVN N

Afdeling for Eksperimentel Medicin har modtaget en delegation fra AAALAC mhp. genakkreditering. Besøget fandt sted den 13.-15. marts 2023. Besøget blev afsluttet med en såkaldt exit briefing, hvor det kom frem at AEM har 2 områder der obligatorisk skal udbedres for at kunne opnå fortsat akkreditering (mandatory findings). Herudover var der 10 punkter med forslag til forbedring.

DIR 35 32 53 33
MOB 40 49 88 21

peter.bollen@sund.ku.dk
<https://emed.ku.dk/>

En af de obligatoriske fund var, at der blev fundet lægemidler, herunder anæstetika/analgetika, som havde overskredet sidste holdbarhedsdato. Dette gjaldt specielt for forskerejede lægemidler i satellitstalde og på eksterne laboratorier. AAALAC anser denne observation for kritisk, fordi anvendelse af lægemidler, som muligvis ikke har den intenderede effekt, udgør en fare for forskningsresultater og dyrevelfærd. Her skal vi bede om jeres hjælp, da personalet på AEM ikke har adgang til medicinskabe på disse afsnit. **Vi vil derfor bede jer om at kassere alle lægemidler med udløbet holdbarhedsdato inden udgangen af april.**


AEM skal indberette dette for at opnå fuld akkreditering inden den 29. marts. Herudover skal vi også sikre at der ikke igen opbevares lægemidler med overskredet sidste holdbarhedsdato. Vi vil gøre dette ved at oplyse herom på følgeseddel ved udlevering af lægemidler, og vil udarbejde en standardprocedure (SOP) som bliver tilgængeligt for alle forskere. Herudover vil AEMs personale fremadrettet fjerne udløbet medicin i de lokaler de har adgang til. I andre lokaler, som satellitstalde og eksterne

laboratorier, er det institutlederens ansvar at sikre at alle medarbejdere er informeret herom og sikrer, at der kun anvendes lægemidler, der overholder sidste holdbarhedsdato.

SIDE 2 AF 3

Konsekvensen af fortsat anvendelse af lægemidler der har overskredet sidste holdbarhedsdato er, at AEM vil miste sin akkreditering. Dette vil have negative følger for fondsansøgninger, herunder NIH grants, som kun tildeles til institutioner med akkrediterede forsøgsdyrsfaciliteter. Jeg håber derfor at alle medvirker i udbedring af denne obligatoriske udbedring.

Med venlig hilsen,

A handwritten signature in black ink, appearing to read 'Bollen', with a large circular flourish underneath.

Peter Bollen
professor, afdelingsleder
Afdeling for Eksperimentel Medicin

RE. MANDATORY FINDINGS DURING AAALAC ACCREDITATION SITE VISIT


The Department of Experimental Medicine has received a delegation from AAALAC regarding re-accreditation. The visit took place on 13-15 March 2023. The visit was concluded with a so-called exit briefing, where it emerged that AEM has 2 areas that must be improved in order to obtain accreditation (mandatory findings). In addition, there were 10 points with suggestions for improvement.

One of the mandatory findings was that medicines and anesthetics were found that had exceeded their expiry date. This is especially so in satellite stables and at external laboratories. Here we must ask for your help, as the staff at AEM do not have access to the medicine cabinets on these sections. **We would therefore like to ask you to dispose of all medicines with an expired shelf life before the end of April.**

AEM must report this to achieve full accreditation by March 29th. In addition, we must also ensure that medicinal products that have exceeded their expiry date are no longer stored. We will do this by stating this on the delivery note when dispensing medicines, and will prepare a standard operating procedure (SOP) that will be available to all researchers. In addition, AEM's staff will in the future remove expired medication in the premises to which they have access. In other rooms, such as satellite stables and external laboratories, it is the responsibility of the head of departments to ensure that all employees are informed about this and observe the expiry date.

The consequence of insufficient compliance with the expiry date of medicines is that the AEM will lose its accreditation. This will have implications for funding applications, especially NIH grants, which are only awarded to institutions with accredited laboratory animal facilities. I therefore hope that everyone contributes to improving this mandatory finding.

With kind regards,



Peter Bollen
Professor, head of department
Department of Experimental Medicine